GSK's global asset sell-off program CDMO took the opportunity to expand.

GSK has been streamlining its global assets in recent years, with the aim of selling assets worth 1bn pounds and raising cash to speed up the public listing of its joint venture with Pfizer, which will focus on drugs and vaccines after the split.
in March, GSK cut a 400-worker Canadian plant and transferred its Mississauga plant and 400 of its workers to Taiwan's BORA Pharmaicals, under which it will continue to produce GSK's existing product line for at least five years.
, GSK has now sold its production site in Poznan, Poland, together with 700 employees, to Delpharm, a French CDMO company, and has signed a contract with Delpharm to continue producing GSK products at the plant for more than five years.
GSK acquired the plant in 1998 and has invested $500 million over the past 20 years, producing 8.7 million tablets and 1.3 million capsules per day by the end of 2018 to export medicines to 130 countries.
's downsizing comes as CDMO is expanding aggressively, with Delpharm acquiring five factories and 1,300 workers from financially troubled rival Famar in November 2019, 17 of Delpharm's plants worldwide, including the Italian preparation plant it acquired from Roche in September 2017.
With the acquisition of Impax Laboratories' 37,000-square-meter aseptic manufacturing plant and GSK Canada plant, the Group has nearly 900 employees, expanding its technical capabilities and scale in the CDMO market and supporting its core North American markets locally.
.